Revenue, 2025

USD 1.68 Billion

Forecast, 2035

USD 3.73 Billion

CAGR, 2026-2035

8.32%

Report Coverage

Global

Animal Drug Compounding Market Key Takeaways

• The animal drug compounding market will likely exceed USD 1.82 billion by 2026.
• Valuation is projected to hit USD 3.73 billion by 2035.
• Estimated to grow at a CAGR of 8.32% starting from 2026 to 2035.
• North America held a major revenue share of 41% of the market in 2025.
• Asia Pacific is expected to be the fastest-growing region during the forecast period.
• By product, the CNS agents segment dominated the market  by 30% share in 2025.
• By product, the hormones & substitutes segment is expected to grow at a rapid CAGR in the coming years.
• By animal type, the companion animal segment registered dominance in the market by 68% share in 2025 & is expected to witness the fastest growth during 2026-2035.
• By route of administration, the oral segment was dominant in the market in 2025.
• By route of administration, the topical segment is expected to grow rapidly in the studied years.
• By dosage form, the suspensions segment led the market by 42% share in 2025.
• By dosage form, the solutions segment is expected to register rapid expansion in the upcoming years.

Animal Drug Compounding Market Trends for 2026

The global animal drug compounding market size was estimated at USD 1.68 billion in 2025 and is predicted to increase from USD 1.82 billion in 2026 to approximately USD 3.73 billion by 2035, expanding at a CAGR of 8.32% from 2026 to 2035.

The current era is facing a huge rise in several infectious conditions among animals, which bolsters demand for innovative, customized medications. Also, regions are emphasizing revolutions in animal wellness through the adoption of advanced telemedicine and online pharmacy solutions.

What are the Immersive Expansions in the Animal Drug Compounding?

The global animal drug compounding market refers to the adoption of tailored therapeutics for animals, which are developed by mixing, altering, or combining ingredients, and should meet extensive compliance guidelines. Moreover, the global market is fueled by a rise in the number of pets & raised pet humanization, which results in demand for human-like care. However, ongoing progression includes the expansion of Mixlab's physical footprint through novel lab acquisitions, providing rapid shipping and more reliable nationwide access to compounded drugs.

Advances in pharmaceutical compounding technologies will continue to improve the accuracy, stability, and safety of formulations. Many veterinary pharmacies are also offering flavored oral suspensions, transdermal gels, customized capsules, and alternative routes of administration that enhance adherence to medication regimens for animals. Additionally, there is a growing demand for personalized veterinary medicines as the use of telemedicine and digital prescription management systems continues to grow; this provides new opportunities for compounders. Lastly, there are increasing investments in veterinary healthcare infrastructure, continued innovation within drug delivery systems, and the availability of new specialty compounded therapies for pain management, skin disorders, endocrine diseases, and cancer, which will contribute to the ongoing growth of the animal drug compounding market in the future.

How is AI Impacting the Growth of the Animal Drug Compounding Market?

Revolutionary efforts in the market are exploring new projects, such as the Virtual Second Species project and other machine-learning-aided multi-scale modeling landscapes (MLMMF), which have designed virtual dog models to estimate toxicological endpoints and examine drug safety without live animals. Alongside, various AI models have been employed to develop personalized drug formulations for over 224 species, especially companion animals, horses, and exotics.

Trends & Future Outlook of the Animal Drug Compounding Market

Strengthening Palatability

The market is emphasizing "feline-friendly" and "canine-friendly" alternatives, like flavored transdermal gels and chewable treats, which enhance owner compliance and lower animal stress.

Spurring Telemedicine Integration

Firms are executing advanced online veterinary pharmacies and telehealth platforms, which are further united with compounding labs to offer direct-to-home shipping of customized medications, mainly for remote or underserved areas.

Focus on Quality Control Protocols

Researchers will step towards the exploration of new, advanced quality control protocols and extensive documentation to ensure the safety, potency, and consistency of compounded products, which highlights issues raised by regulatory bodies, especially the FDA.

Quick Facts Table

Segmentation Analysis

Product Insights

Which Product Dominated the Animal Drug Compounding Market in 2025?

In 2025, the CNS agents segment captured the biggest share of 30% of the market. Expanding awareness regarding neurological/behavioral conditions, such as anxiety, epilepsy, pain, and diversity of these agents, including anticonvulsants, anxiolytics, analgesics, sedatives, and antidepressants are propelling the segmental growth. The market is focusing on developing flavored oral oil suspensions, chewable tablets, and transdermal gels/patches for CNS agents, which makes easy administration for pet owners and reduces stress on animals.

Hormones & Substitutes

Whereas, the hormones & substitutes segment is anticipated to expand rapidly. These products are acquiring attention among veterinary practitioners for their distinguished potency and effectiveness in hormonal replacement therapy. Also, they have a vital role in treating endocrine disorders, like hyperthyroidism in cats & for reproductive management. The year had widened compounded altrenogest for estrus suppression and pregnancy support in horses, coupled with diverse vitamin-hormone supplements for livestock reproductive health.

Animal Type Insights

How did the Companion Animal Segment Lead the Market in 2025?

The companion animal segment was dominant in the animal drug compounding market by 68% share in 2025 & will expand fastest. The raised adoption of compounding facilitates customized doses, flavors, such as fish for cats, beef for dogs, and forms, like gels, liquids for easier administration, with optimized compliance. The globe is putting efforts into the rising use of semi-solid extrusion (SSE) 3D printing to design chewable, precisely-dosed tablets for veterinary clinic preparation.

Route of Administration Insights

Why did the Oral Segment Dominate the Market in 2025?

In 2025, the oral segment held the largest revenue share of 48% of the market. More specifically, this route provides ease, non-invasiveness, and greater compliance for both pets and livestock. The latest solutions comprise oral transmucosal gels, which are an option for animals that resist swallowing drugs, with enhanced absorption for specific drugs, particularly compounded buprenorphine. Day by day, pharmacies are widely using automated mixing systems and cloud-based prescription platforms to accelerate the precision and accuracy of dosing in oral therapeutics.

Topical

In the future, the topical segment is predicted to witness the fastest expansion. Owners and practitioners are highly using creams, gels, and sprays to treat localized conditions, specifically infections, wounds, parasites, like fleas, ticks, mites, and dermatitis. However, transdermal gels/patches are broadly adopted as pain relievers or anti-anxiety meds. Nowadays, the market is implementing advanced nanotechnology, particularly nanogels and liposomes, to boost topical delivery by raising drug penetration, offering controlled release, and also enabling targeted action.

Dosage Form Insights

How did the Suspensions Segment Lead the Market in 2025?

In 2025, the suspensions segment registered dominance in the animal drug compounding market by 42%. This dosage form is highly suitable for pediatric, geriatric, and exotic animals, as they offer accurate dosing and can mask unpleasant tastes, with crucially improved compliance in pets compared to solid forms. Researchers are working on long-acting injectable suspensions, often using oil-based vehicles or depot systems, which emphasize maintaining therapeutic levels over extended periods.

Solutions

The solutions segment is estimated to expand rapidly. They have prominent benefits over the other forms, such as quicker absorption, ease of administration, accurate dosing, and expanded stability. A recent development covers the launch of a patented injectable omeprazole solution for equine gastric ulcers developed by Epicur Pharma and Bova as an innovative administration route for horses. Recently, FDA-approved Otiserene, a single-dose, long-acting otic suspension that acts as a liquid for application but remains in the ear for sustained therapy.

Regional Insights

How did North America Dominate the Market in 2025?

North America registered dominance in the animal drug compounding market by 41% share in 2025, due to the increasing pet ownership, wider emphasis on animal wellness, and robust veterinary infrastructure. As of late 2025, Health Canada is guiding on "Agile Licensing" regulations, which enable terms and conditions (T&Cs) for all drugs, comprising veterinary products, to highlight extensive evidence for debilitating concerns.

U.S. Market Trends

The U.S. dominated the market with a major share in 2025. This is led by the ongoing FDA upgradation to its "List of Bulk Drug Substances for Compounding Office Stock Drugs" under Guidance for Industry (GFI) #256, which allows application discretion for specific drugs required for urgent care.

Canada Market Trends

Canada has a growing animal drug compounding market, which is being aided by the increasing number of pets owned by people, an increased interest in buying customized vet medications, and a rise in how much money is being spent on animal healthcare. There are many vet clinics and specialty pharmacies that are turning to compounded formulations in order to improve the dosing accuracy, palatability, and compliance of treatment for both companion animals and livestock.

Mexico Market Trends

Mexico's animal drug compounding market also continues to see growth due to the expansion of veterinary services, increased production of livestock, and the trend of humanization of pets. The demand for customized drug medications continues to rise, as veterinarians are looking for customized medication solutions to meet the unique therapeutic needs of the variety of species they treat and the specific treatment requirements of the individual animal.

Escalating Veterinary Facilities & Technological Advances are Driving the Asia Pacific

Asia Pacific is anticipated to show the fastest growth in the market, as the region is spurring specialized veterinary clinics and compounding pharmacies in countries, mainly in China and India. Alongside, the region is fostering AI-assisted dose-form personalization, which lowers formulation cycle times. Recently, My Compounding, a Brisbane-based pharmacy, broadened its operations nationwide to offer bespoke veterinary compounding, like transdermal gels and allergy-friendly formulas across substantial Australian cities to find hard-to-treat cases in domestic pets and livestock.

China Market Trends

In China, the animal drug compounding market is predicted to expand rapidly, as recently the Ministry of Agriculture and Rural Affairs (MARA) executed stringent veterinary drug registration guidelines that demand comprehensive, accurate data for novel products. This also further encompasses on-site inspections for non-compliant applications to ensure data authenticity and raised manufacturing standards.

India Market Trends

India represents an extremely high growth opportunity for animal drug compounding due to the size of its overall livestock population, the growth of the companion animal population, and increasing awareness of animal health. There is also a growing demand for species-specific formulations, flavoured medications, and custom dosage forms, which makes compounding more attractive to veterinarians and animal care professionals.

Japan Market Trends

Japan benefits from a high percentage of pet ownership; increased spending on companion animal health care; and increased demand for individualized veterinary treatment in its animal drug compounding market. As a result, veterinarians are continuing to utilise compounded medications as a way to manage dosing issues and improve compliance with treatment for ageing pets.

Empowering Control on Antimicrobials & Antiparasitics is Fueling Europe

Europe is experiencing a notable growth in the market, as the region is shifting towards combating antimicrobial resistance (AMR) by enforcing new regulations and stricter restrictions on the preventative use of antimicrobials. Recently, all antiparasitics in Ireland need a veterinary prescription, moving them from over-the-counter status.

UK Market Trends

Recently, in the UK, a novel UK-wide licensing regime for human medicines was developed, but a two-tier system for veterinary medicinal products remains. Whereas the VMD facilitated rigorous guidance for the supply of veterinary medicines to Northern Ireland to ensure continued access.

Netherlands Market Trends

The Netherlands is showing steady growth in the compounding of animal drugs through a significant market for veterinary healthcare services and a commitment to animal welfare. With an increasing demand for customized medications for both pets and livestock, the compounding of drugs has increased the effectiveness of therapy and the ease of administering such therapies.

Argentina Market Trends

The Argentine animal drug compounding market is fueled by Argentina's growing number of livestock and pet owners looking for customized veterinary medicine. The growing need for custom veterinary prescriptions, especially for livestock, but also for specialized conditions,  is creating a growing market for the use of compounded veterinary drugs to deliver therapeutic results and address unique health care needs.

Market Ecosystem Analysis

Value Chain Analysis

R&D

• R&D focuses on identifying veterinary needs, formulating customized compounds, sourcing active ingredients, conducting stability testing, optimizing dosage forms, and ensuring quality documentation for reproducible, patient-specific animal therapies safely globally.
• Companies involved include Wedgewood Pharmacy, Bimeda, Covetrus compounding units, and specialized veterinary compounding laboratories.

Clinical trials & regulatory approvals

• Clinical trials and regulatory approvals involve safety validation, efficacy assessments, species-specific studies, compliance with veterinary guidelines, documentation submission, audits, and ongoing pharmacovigilance to meet national compounding regulations standards requirements.
• Companies involved include regulatory consulting firms, veterinary CROs, IDEXX advisory services, and compliance divisions of compounding pharmacies.

Distribution to hospitals & pharmacies

• Distribution to hospitals and pharmacies includes order processing, cold chain management where required, customized packaging, prescription verification, logistics coordination, timely delivery, inventory control, and post delivery support services nationwide.
• Companies involved include Covetrus, McKesson Animal Health, Patterson Veterinary Supply, UPS Healthcare, and regional veterinary distributors.

Key Players' Offerings in the Animal Drug Compounding Market

Market Share Influence Assessment

Competitive Landscape

SWOT Analysis: Animal Drug Compounding Market

Strengths

• High Customization Capacity: Ability to alter dosage forms, strengths, and flavors (e.g., creating palatable liquids or chewable tablets) improves patient compliance, particularly for cats and exotic animals.
• Filling Therapeutic Gaps: Provides necessary medication when no FDA-approved alternative exists, such as producing cisapride for feline constipation or specific hormonal replacements.
• Strong Demand in Companion Animal Sector: The companion animal segment (especially dogs and cats) dominates the market, supported by rising pet expenditures and owners treating pets as family members.

Weaknesses

• Lack of Regulatory Standardization: Stringent, varied regulations across regions (and within the U.S.) lead to inconsistencies in quality, stability, and safety standards for compounded drugs.
• Risk of Inaccuracy and Contamination: Compounded drugs are not subject to the same rigorous FDA approval process as commercial drugs, increasing the risk of over- or under-potent medication.

Opportunities

• Expansion of 503B Outsourcing Facilities: Growing investment in 503B facilities which operate under stricter GMP conditions allows for larger batches, improved quality, and national shipping to veterinary clinics.
• Emerging Market Growth (Asia-Pacific/LATAM): Rapidly rising pet ownership and improving veterinary infrastructure in regions like China, India, and Brazil offer high potential for market expansion.
• Innovation in Delivery Systems: Development of advanced dosage forms, such as transdermal gels and long-acting injectables, reduces stress during medication administration and improves therapeutic outcomes.

Threats

• Stricter FDA Enforcement (GFI #256): Increased scrutiny on using bulk drug substances to create "copies" of approved drugs restricts certain compounding practices and increases compliance burdens.
• High Operating and Compliance Costs: The need for specialized equipment, specialized staff, and stringent documentation (e.g., USP 800 for hazardous drugs) creates significant financial burdens for smaller compounders.

Latest Announcements by Industry Leader

• In January 2025, Revelation Pharma announced the launch of Revelation Animal Health, a dedicated division providing customized compounded medications for companion animals, exotics, zoos, and aquariums nationwide. CEO Shawn Hodges stated, “Revelation Animal Health presents an opportunity to further the values and quality care of the Revelation Pharma network by expanding our offerings to the entire family, human and animal alike. We are excited to be able to fill the need for top-quality, customized compounding for animals across the country.”
• In December 2025, CurifyLabs announced the launch of CuraBlend® Vet, a veterinary excipient system enabling 3D-printed, personalized medicines for pets. CEO Charlotta Topelius stated, “Pet owners want medication time to be simple, not stressful. CuraBlend® Vet gives pharmacists a reliable way to make pet-friendly medicines that animals actually want to eat.”

What are the Key Developments in the Animal Drug Compounding Market?

• In December 2025, Curifylabs launched Curablend Vet, a novel veterinary excipient system that allows 3D-printed, palatable, and tailored medicines for pets.
• In September 2025, Zydus Life Science's subsidiary, ZyVet Animal Health, unveiled the first FDA-cleared generic veterinary medication for canine urinary incontinence and congestive heart failure in dogs and cats.

Segments Covered in the Report

By Product

• Anti-infective Agents
• Anti-inflammatory Agents
• Hormones & Substitutes
• CNS Agents
• Other Products

By Animal Type

• Companion Animal
• Dogs
• Cats
• Others
• Livestock Animal

By Route of Administration

• Oral
• Injectable
• Topical
• Other Routes

By Dosage Form

• Suspensions
• Solutions
• Capsules

By Region

• North America
  • U.S.
  • Canada
  • Mexico
  • Rest of North America
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Europe
  • Western Europe
    • Germany
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal
    • Belgium
    • Ireland
    • UK
    • Iceland
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe
    • Austria
    • Russia & Belarus
    • Türkiye
    • Albania
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • Taiwan
  • India
  • Japan
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea
  • Rest of APAC
• MEA
  • GCC Countries
    • Saudi Arabia
    • United Arab Emirates (UAE)
    • Qatar
    • Kuwait
    • Oman
    • Bahrain
  • South Africa
  • Egypt
  • Rest of MEA